Authors
Akriti Agrawal, Emilee M Dreifus, Antonella Tosti
Published in
Expert opinion on pharmacotherapy. Jun 15, 2026. Epub Jun 15, 2026.
Abstract
Androgenetic alopecia (AGA) is the most common form of hair loss, characterized by androgen-dependent follicular miniaturization. To date, topical and oral minoxidil, 5-α-reductase inhibitors and oral antiandrogens remain the mainstay of treatment, but research is progressing fast in the search of new mechanism-targeted pharmacotherapies.
This article summarizes emerging therapies for AGA and highlights their underlying mechanisms. A targeted review was conducted of PubMed, ClinicalTrials.gov, Food and Drug Administration available resources, company-press releases and published abstracts from database inception through December 2025.
Recent advances in hair biology and drug development have led to a paradigm shift toward new strategies to prevent androgen effects on the follicle, improve minoxidil delivery, activate follicle stem cells and prevent follicular apoptosis. These include topical androgen-receptor antagonists and degraders (clascoterone, GT20029), biologics targeting prolactin receptor inhibition (HMI-115, ABS-201), anagen-inducing injectables (AMP-303), metabolic and follicular activators (PP405, ET-02), thyroid hormone receptor-β agonists (KB-141), optimized potassium channel opener delivery systems (extended-release and sublingual minoxidil) and modulation of longevity pathways using rapamycin and metformin. Collectively, these newer pharmacotherapeutics aim to improve efficacy, safety, and patient adherence. Ongoing and future clinical trials will determine their definitive role in reshaping the therapeutic landscape of androgenetic alopecia.
PMID:
42290527
Bibliographic data and abstract were imported from PubMed on 15 Jun 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 9
- Comments 0